Adenocarcinoma is the most common malignant neoplasm of the gallbladder, but squamous cell carcinoma (SCC) is rare with an incidence of 1.4 approximately 3.3%. We present a recent case of a 63-year-old man complaining of abdominal distention. Preoperative US and CT revealed a large tumor of the gallbladder infiltrating the liver and transverse colon. Cholecystectomy, subsegmental resection of the liver, lymph node dissection, and partial resection of the transverse colon were performed. The resected specimen was histologically diagnosed as SCC without nodal metastases.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1272/jnms.71.417 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A deep learning-based clinical-radiomics model predicting the treatment response of immune checkpoint inhibitors (ICIs)-based conversion therapy in potentially convertible hepatocelluar carcinoma patients: a tumour marker prognostic study.
Int J Surg
March 2025
Department of Hepatobiliary Surgery, Sun Yat-Sen Memorial Hospital, Guangzhou, Guangdong, China.
Background: The majority of patients with hepatocellular carcinoma (HCC) miss the opportunity of radical resection, making ICIs-based conversion therapy a primary option. However, challenges persist in predicting response and identifying the optimal patient subset. The objective is to develop a CT-based clinical-radiomics model to predict durable clinical benefit (DCB) of ICIs-based treatment in potentially convertible HCC patients.
View Article and Find Full Text PDFWe present a smartphone-based bimodal device (SBBD) combining fluorescence imaging and spectroscopy for a noninvasive, portable, cost-effective, and real-time diagnosis of oral precancer. The device employs a 405 nm laser excitation to capture native fluorescence from intrinsic biomarkers, including flavin adenine dinucleotide (FAD) and porphyrin, across 136 subjects representing normal, OPMD, and OSCC. The fluorescence imaging module identifies regions of interest (ROI) based on the red-to-green band ratio (porphyrinFAD), while the spectroscopy module confirms findings through multiple point measurements.
View Article and Find Full Text PDFCharacteristics and Prognostic Markers of Aggressive Subtypes of Thyroid Cancer: A Retrospective Study.
Cancer Rep (Hoboken)
March 2025
Division of Endocrinology and Metabolism, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.
Objective: The prevalence of thyroid cancer has increased significantly. Aggressive subtypes of papillary thyroid cancer (AG-PTC) and high-grade follicular cell-derived malignancies (HGFM) are malignancies that lie between well-differentiated and undifferentiated cancers, and their management needs to be clarified. The aim of our study is to describe the clinicopathological characteristics of AG-PTC and HGFM and to assess their prognostic value.
View Article and Find Full Text PDFEfficacy of measuring natural killer-activating receptor ligands to predict the pathogenesis of metabolic dysfunction-associated steatotic liver disease.
Hepatol Int
March 2025
Department of Gastroenterology, Aichi Medical University, 1-1 Yazakokarimata, Nagakute, Aichi, 480-1195, Japan.
Objective: The proportion of non-B/non-C hepatocellular carcinoma cases is increasing, and the principal cause is metabolic dysfunction-associated steatotic liver disease (MASLD). The degree of intrahepatic natural killer (NK) cell infiltration has been reported to correlate with MASLD progression. However, reports on MASLD are limited.
View Article and Find Full Text PDFEfficacy and safety of immunotherapy plus chemotherapy in advanced or metastatic pulmonary large-cell neuroendocrine carcinoma.
Discov Oncol
March 2025
Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, and Shandong Academy of Medical Sciences, Jinan, 250000, China.
Background: Patients with advanced pulmonary large-cell neuroendocrine carcinoma (LCNEC) have a progressive clinical course and poor prognosis, and effective treatment options remain limited. This study assessed the efficacy and safety of immunotherapy plus chemotherapy for advanced LCNEC.
Methods: We retrospectively collected medical records of patients with advanced LCNEC who attended Shandong Cancer Hospital from January 2018 to December 2022.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!